Health · 2 views
Subcutaneous Risankizumab Induction Improved Outcomes in Crohn's Disease
(MedPage Today) -- Subcutaneous risankizumab (Skyrizi) induction therapy significantly improved clinical remission and endoscopic response rates in patients with moderately to severely active Crohn's disease, results from the phase III…
Summary
(MedPage Today) -- Subcutaneous risankizumab (Skyrizi) induction therapy significantly improved clinical remission and endoscopic response rates in patients with moderately to severely active Crohn's disease, results from the phase III AFFIRM trial
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Molecular imaging demonstrates promise for predicting complete pathologic response in HER2-positive breast cancerContinue reading
- Persistent gaps remain in hearing aid coverage, especially for older and lower-income adults, study findsContinue reading
- First At-Home Thyroid Eye Disease Shot ApprovedContinue reading
- Intermittent hemodialysis not noninferior to continuous renal-replacement therapyContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow